SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy
Weitao Shen, Wei Zhang, Weilin Ye, Haihong Wang, Qingxi Zhang, Jie Shen, Qingsha Hong, Xiang Li, Ge Wen, Ting Wei, Jian Zhang
Abstract
: Our study provided a novel viewpoint indicating that the REV-ERB agonist SR9009 could be a novel and promising therapeutic strategy in first- or second-line SCLC treatment. The anti-SCLC effect of SR9009 is mediated by REV-ERB dependent suppression of autophagy via direct repression of the autophagy gene Atg5.
Topics & Concepts
AutophagyLung cancerCancer researchCell biologyChemistryCellMedicineBiologyApoptosisPathologyBiochemistryAutophagy in Disease and TherapyRNA modifications and cancerEndoplasmic Reticulum Stress and Disease